Type 1 Diabetes
Artikler
With Grandma as Inspiration: Refusing to Let the Diagnosis Limit Her
Silje Elfrida (36) lives in Tjodalyng, near Larvik, works in the healthcare sector, and leads a busy life with two very active sons aged seven and five. At the same time, she is navigating an uncertain romantic situation. Diagnosed with type 1 diabetes at the age of 19 in 2007, Silje Elfrida took on the challenge immediately, determined not to let the condition limit her life.
Ingunn’s Son Was Diagnosed with Type 1 Diabetes: "I Wish I Had Known More in Advance"
Unpredictable blood glucose readings, extreme fatigue, and an overwhelming fear of low blood glucose—this is how Ingunn describes the early days after her son, Olav, was diagnosed with type 1 diabetes. It has been a time of sleepless nights and many worries. But it has also been a time of learning, adaptation, and strengthened family bonds.
Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!
Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.1 The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.2 Assays for detecting autoimmune T1D have shown high sensitivity and specificity.3,4
Autoimmune Type 1 Diabetes
The Type 1 Diabetes (T1D) field is evolving.
Recognition of the presymptomatic stages in T1D is growing.1-4
The clinical benefits of early detection of T1D are being highlighted.3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.1,2
Glycaemic Targets and Vascular Complications in Type 2 Diabetes: What Are the Thresholds?
Summary of Zoungas S, et al. Diabetologia. 2012;55:636–643.
Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?
Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.
Utdannelse
Personalized approach in T2D is key for success
The Sanofi webinar ‘Act Now for Impact: Glycemic Control and Beyond’ focuses on recent advancements in treating type 2 diabetes (T2D), emphasizing a personalized approach for better outcomes. Prof. Frank Nobels (Belgium), prof. De Galan (the Netherlands) and Prof Björn Eliasson (Sweden) addressed various aspects of T2D treatment in the present era.
.svg)
.svg)